Absorption of glucagon-like peptide-1 can be protracted by zinc or protamine

被引:10
作者
Pridal, L [1 ]
Agerbaek, H [1 ]
Christensen, LN [1 ]
Thomsen, K [1 ]
Kirk, O [1 ]
机构
[1] NOVO NORDISK AS,PHARMACEUT DEV,DK-2880 BAGSVAERD,DENMARK
关键词
glucagon-like peptide-1; GLP-1(7-36)amide; sc preparations; zinc; protamine; pharmacokinetics;
D O I
10.1016/0378-5173(95)04480-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacokinetics of several different preparations for subcutaneous administration of GLP-1(7-36)amide (GLP-1) were studied. The difference between soluble GLP-1 at pH 4.0 and a suspension of GLP-1 crystals at pH 6.9, and how addition of zinc chloride or protamine sulphate to the GLP-1 suspension affected the absorption kinetics after s.c. administration, were investigated. Four Beagle dogs received 50 mu g/kg of GLP-1 s.c. in different vehicle compositions. The vehicle contained 1 mg/ml of GLP-1, 10 mmol/l disodium phosphate, 16 mg/ml glycerol, and in some preparations either zinc chloride or protamine sulphate. The preparations were: (1) pH 4.0, (2) pH 6.9, (3) 1 equiv. (relative to GLP-1) zinc chloride pH 6.9, (4) 0.5 equiv. zinc chloride pH 6.9, (5) 3 equiv. zinc chloride pH 6.9, (6) 0.5 mg/ml protamine sulphate pH 4.0, and (7) 0.5 mg/ml protamine sulphate pH 6.9. Plasma samples were analyzed employing a sandwich enzyme-linked immunosorbant assay. Addition of zinc chloride or protamine sulphate to the GLP-1 suspension decreased the absorption rate. The plasma concentration of GLP-1 was increased to a pharmacological level for at least 15 h when administered s.c. as a zinc or protamine suspension. Furthermore, the peak plasma concentration was flattened out, when the peptide was administered as a suspension containing zinc chloride or protamine sulphate, compared to a solution.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 15 条
  • [1] ADELHORST K, 1994, J BIOL CHEM, V269, P6275
  • [2] BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS
    DEACON, CF
    NAUCK, MA
    TOFTNIELSEN, M
    PRIDAL, L
    WILLMS, B
    HOLST, JJ
    [J]. DIABETES, 1995, 44 (09) : 1126 - 1131
  • [3] GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE SECRETION IN RESPONSE TO NUTRIENT INGESTION IN MAN - ACUTE POSTPRANDIAL AND 24-H SECRETION PATTERNS
    ELLIOTT, RM
    MORGAN, LM
    TREDGER, JA
    DEACON, S
    WRIGHT, J
    MARKS, V
    [J]. JOURNAL OF ENDOCRINOLOGY, 1993, 138 (01) : 159 - 166
  • [4] IMPROVING INSULIN THERAPY - ACHIEVEMENTS AND CHALLENGES
    GALLOWAY, JA
    CHANCE, RE
    [J]. HORMONE AND METABOLIC RESEARCH, 1994, 26 (12) : 591 - 598
  • [5] ANTIDIABETOGENIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE IN NORMAL SUBJECTS AND PATIENTS WITH DIABETES-MELLITUS
    GUTNIAK, M
    ORSKOV, C
    HOLST, JJ
    AHREN, B
    EFENDIC, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (20) : 1316 - 1322
  • [6] SUBCUTANEOUS INJECTION OF THE INCRETIN HORMONE GLUCAGON-LIKE PEPTIDE-1 ABOLISHES POSTPRANDIAL GLYCEMIA IN NIDDM
    GUTNIAK, MK
    LINDE, B
    HOLST, JJ
    EFENDIC, S
    [J]. DIABETES CARE, 1994, 17 (09) : 1039 - 1044
  • [7] Heinzel G., 1993, PHARMACOKINETIC PHAR
  • [8] NORMALIZATION OF FASTING HYPERGLYCEMIA BY EXOGENOUS GLUCAGON-LIKE PEPTIDE-1 (7-36 AMIDE) IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS
    NAUCK, MA
    KLEINE, N
    ORSKOV, C
    HOLST, JJ
    WILLMS, B
    CREUTZFELDT, W
    [J]. DIABETOLOGIA, 1993, 36 (08) : 741 - 744
  • [9] ORSKOV C, 1992, DIABETOLOGIA, V35, P701
  • [10] PINGEL M, 1993, HDB EXPT PHARM, V66, pCH8